I'd say the exact opposite is true. Their (Novatis) case for inclusion was pretty weak and they now have the premier American authority on Urology specifically mentioning them. I'd say there's a very likely chance of getting this coverage discision overturned in PEB's favour.
Ann: Cxbladder Incorporated into AUA Clinical Guideline, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.95M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10450 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 10865 | 2 |
View Market Depth
| Last trade - 16.21pm 25/06/2025 (20 minute delay) ? |
| PEB (ASX) Chart |
Day chart unavailable